<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990405</url>
  </required_header>
  <id_info>
    <org_study_id>KoreanCHUGR05</org_study_id>
    <nct_id>NCT00990405</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia</brief_title>
  <official_title>Phase 4 Study of Helicobacter Pylori Eradication Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korean College of Helicobacter and Upper Gastrointestinal Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korean College of Helicobacter and Upper Gastrointestinal Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of Helicobacter pylori infection in functional dyspepsia remains controversial.
      Several randomized controlled trials in western countries have shown no significant advantage
      over placebo. But some recent studies in Asian population were different compared to the
      result of studies in the Western population. At the present time, it seems to be difficult to
      conclude the efficacy of the H.pylori eradication therapy in patients with H. pylori-infected
      functional dyspepsia.

      The investigators hypothesize that eradication of Helicobacter pylori has a sustained global
      symptom improvement in patients with H. pylori infected functional dyspepsia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Functional dyspepsia: diagnosed by Rome III criteria of Functional gastrointestinal disorder
      Treatment regimen: Combination of proton pump inhibitor, Amoxicillin, Clarithromycin for 7
      days Placebo: Same shaped placebo drugs
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global symptom improvement after eradication of Helicobacter pylori in patients with functional dyspepsia therapy)</measure>
    <time_frame>Symptom assessment at 8 weeks after eradication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To improves the quality of life</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global symptom improvement, at 4 weeks after Helicobacter pylori eradication therapy</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The improvement of 8 dyspeptic symptom</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The adequate relief of symptom</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Functional Dyspepsia</condition>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Lansoprazole+Clarithromycin+Amoxycillin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprzole+Amoxicillin+Clarithromycin</intervention_name>
    <description>Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days</description>
    <arm_group_label>Lansoprazole+Clarithromycin+Amoxycillin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Functional dyspepsia by Rome III criteria

          -  Normal endoscopic findings

          -  H. pylori positive by Urea breath test

        Exclusion Criteria:

          -  Patients with severe concomitant systemic disease

          -  Patients with GI surgery

          -  Females with pregnancy or breast-feeding

          -  Irritable bowel syndrome, inflammatory bowel disease

          -  Duodenal Ulcer, Gastric Ulcer, GI bleeding

          -  History of eradication therapy of Helicobacter pylori

          -  Malignancy

          -  Psychosomatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-Young Seol, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Korean Society of Helicobacter and Upper Gastrointestinal Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korean Society of Helicobacter and Upper GI Research</name>
      <address>
        <city>Seoul</city>
        <zip>135-87</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2009</study_first_submitted>
  <study_first_submitted_qc>October 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2009</study_first_posted>
  <last_update_submitted>October 5, 2009</last_update_submitted>
  <last_update_submitted_qc>October 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Seol, Sang-Young/President</name_title>
    <organization>Korean Society of Helicobacter and Upper Gastrointestinal Research</organization>
  </responsible_party>
  <keyword>Rome III criteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

